HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
At HTL Biotechnology, we put our expertise in biopolymers at the service of medical innovation. With 100% French-based production and the highest quality standards, we support laboratories worldwide in developing safe, effective, and sustainable therapeutic solutions.
Moments like these are essential to anticipate market evolutions and to continue building, together with our partners, the innovations of tomorrow.
Ophthalmic diseases affect millions of patients worldwide and demand innovative, reliable, and differentiating solutions. We strongly believe that biopolymers have the potential to transform how these conditions are treated.
By supporting hydration, ocular protection, and serving as vectors for innovative drug delivery strategies, these biomaterials are becoming essential allies for the therapies of tomorrow.
At ESCRS 2025, we shared our conviction: ophthalmology is entering a new era, and HTL Biotechnology is proud to contribute to this transformation alongside its partners.
Feel the difference with HTL Inside.
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
HTL Biotechnology hosted a scientific summit in Chengdu, China, dedicated to PDRN/PN, bringing together more than 130 experts and professionals to discuss the latest scientific advances, regulatory developments and emerging applications.
Driven by the collective commitment of our teams, this report confirms the maturity of an internationally recognized approach, which was recognized this year with the EcoVadis Platinum medal, placing HTL Biotechnology among the top 1% of the world’s most committed companies.